SEC charges Cassava over 'misleading' Alzheimer's claims
The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former head of neuroscience Dr Lindsay Burns of misleading investors by announcing that the company’s small-molecule therapeutic simufilam significantly improved patient cognition in the phase 2b study.
SEC Charges Cassava Sciences, Former Executives for Misleading Claims in Alzheimer's Trial
Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic treatment of Alzheimer's disease,
Cassava Sciences SAVA has agreed to pay a $40 million fine to settle charges from the U.S. Securities and Exchange Commission ...
Cassava Sciences, Inc. (NASDAQ:SAVA) on Tuesday announced the completion of an interim safety review of its Alzheimer's drug ...
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...
Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District Court of Texas, claiming that the company misled investors regarding the Phase ...
Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended ...
Shares of Cassava Sciences, Inc (NASDAQ:SAVA) dropped 11.5% in pre-open trade on Friday following the company's statement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback